IVM has demonstrated in vivo efficacy against WNT-TCF-dependent human colon cancer and lung carcinoma xenografts, but not against WNT-TCF-independent tumours, suggesting specific blockade of the WNT-TCF response [64]. This evidence concerns the gene HNF4A and malignant colon neoplasm.